Epirubicin Dosing and Body Surface Area
Author Information
Author(s): NA Dobbs, CJ Twelves
Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital, London
Hypothesis
Does adjusting epirubicin doses for body surface area affect pharmacokinetics and pharmacodynamics?
Conclusion
Adjusting epirubicin doses based on body surface area does not reduce variability in drug clearance or myelosuppression.
Supporting Evidence
- Unadjusted plasma clearance did not correlate with body surface area.
- There was no significant difference in variability between adjusted and unadjusted clearance.
- Neutropenia patterns were similar regardless of dose adjustment for surface area.
Takeaway
Doctors usually change cancer drug doses based on how big a person is, but this study found that it doesn't really help with how the drug works or its side effects.
Methodology
The study evaluated epirubicin pharmacokinetics in 32 women with advanced breast cancer, measuring drug levels and effects without prior anthracycline treatment.
Potential Biases
Potential bias in treatment doses due to patient age and fitness levels.
Limitations
The study had a relatively narrow range of surface areas among participants.
Participant Demographics
All participants were women with advanced breast cancer, aged 35-75 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website